BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $557.00. The company's shares closed today at $441.97.
Confident Investing Starts Here:
According to TipRanks, Seigerman is a 4-star analyst with an average return of 3.7% and a 43.73% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Novo Nordisk, and Vertex Pharmaceuticals.
In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from UBS's Eliana Merle in a report issued yesterday. However, today, Barclays maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
CrowdStrike Named a Customers' Choice in the 2025 Gartner® Peer Insights™ ‘Voice of the Customer' for User Authentication Report
AUSTIN, Texas--(BUSINESS WIRE)-- CrowdStrike (NASDAQ: CRWD) today announced its recognition as a Customers' Choice in the 2025 Gartner Peer Insights™ 'Voice of the Customer' for User Authentication report. CrowdStrike has the most 5-star ratings of any vendor evaluated in the report and has a 97% Willingness to Recommend rating, based on 206 overall responses as of February 28, 2025. 'Today's adversaries aren't breaking in – they're logging in. Attackers use stolen credentials and social engineering to gain initial access, then exploit vulnerabilities and abuse remote access tools to escalate privileges and move laterally across environments,' said Elia Zaitsev, chief technology officer, CrowdStrike. 'The Falcon platform is the only solution that stops identity-based attacks at every stage, from initial compromise to lateral movement, across hybrid environments. We believe this recognition validates Falcon as the platform of choice for organizations looking to close protection gaps, reduce complexity, and stop evolving threats with unified, AI-powered protection.' What Customers Are Saying As a native part of the CrowdStrike Falcon® platform, Falcon® Identity Protection stops sophisticated cross-domain and insider threats spanning identity, endpoint, and cloud. Customer reviews highlight the power of CrowdStrike's unified platform and advanced AI to prevent, detect, and respond to identity-based attacks: CrowdStrike Falcon Provides Robust Defense Against Identity Attacks: "CS Falcon Identity Protection is a seamless solution that provides a robust layer of defense against Identity based attacks. It works by incorporating a native AI/ML based threat detection approach to several Identity management solutions like Active Directory being used in an organization. This is achievable using the agent being used for EPP. No separate deployment is required." – IT Security Engineer, Software Industry CrowdStrike Falcon Identity Protection - Protector of the Realm: 'The ability to detect and prevent identity based attacks and account takeover with real-time monitoring makes it an excellent choice. Integration with leading platforms and automated threat response capabilities make it adaptable. With its AI-driven detection and cloud-native architecture, Falcon Identity Protection offers strong prevention capabilities and advanced threat detection makes it the best choice for businesses seeking to enhance their security in the modern era.' – Engineer - ITS Security, Software Industry Navigating Real-Time Scanning and Identifying Threats: 'It is an exceptional tool for securing user identities & preventing breaches. With its AI-driven detection, it provides protection against account takeovers, credential stuffing, & other identity-based attacks. Its robust features make it ideal for protecting user identities.' – IT Lead, Banking Industry Why Our Customers Choose Falcon Identity Protection CrowdStrike's leadership in identity security is built on its unified platform architecture and deep understanding of real-world adversary tradecraft, delivering: End-to-End Hybrid Identity Security: Identity is under relentless attack, and the rise of agentic AI is fueling a surge in machine identities. CrowdStrike provides the only unified platform that secures both human and non-human identities at every stage of the attack – from initial compromise to privilege escalation with Falcon® Privileged Access, and lateral movement – across hybrid environments. AI-Powered, Adversary-Driven Approach: Falcon Identity Protection is powered by real-time signals from endpoints and devices, threat intelligence from frontline experts, and trillions of daily security events. This data advantage creates a continuous feedback loop that enables AI-driven protection to prevent, detect, and respond to identity-based attacks. Agentic AI Innovation: CrowdStrike brings the power of agentic AI to Falcon Identity Protection with Charlotte AI Agentic Detection Triage, which autonomously triages cross-domain attack detections with over 98% accuracy to rapidly prioritize the most critical threats. Cross-Domain Protection: Falcon Identity Protection stops sophisticated cross-domain and insider threats spanning identity, endpoint, and cloud. By sharing telemetry and intelligence across Falcon platform modules, CrowdStrike's unified architecture exposes attack paths and stops breaches before impact. Additional Resources To learn more about CrowdStrike's recognition in the 2025 Gartner Peer Insights™ 'Voice of the Customer' for User Authentication report, please visit our website and read our blog. To learn more about Falcon Identity Protection, please visit our website. Gartner Disclaimer GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose. About CrowdStrike CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world's most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data. Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting and prioritized observability of vulnerabilities. Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity and immediate time-to-value. CrowdStrike: We stop breaches. © 2025 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.
Yahoo
12 minutes ago
- Yahoo
Strategy (MSTR) Soars 132% in 12 Months as AI and Bitcoin Strategy Pays Off
June 4 - Strategy (NASDAQ:MSTR) stock has climbed about 27% year-to-date and surged 132% over the past 12 months, as investors view it as a leading Bitcoin treasury company with AI analytics capabilities. Warning! GuruFocus has detected 9 Warning Signs with MSTR. The firm, formerly known as MicroStrategy, holds 580,955 Bitcoins, having purchased 705 coins for $75.1 million between May 26 and June 1. Its strategy combines proceeds from equity and debt financings with operational cash flow to build its BTC holdings. On June 2, Strategy launched an offering of 2.5 million shares of Series A Perpetual Stride Preferred Stock, intending to use net proceeds for additional Bitcoin acquisitions and general corporate purposes, including working capital. Wells Fargo analysts said Bitcoin is entering an institutional phase, with new Bitcoin treasury corps emerging after MicroStrategy's success. They highlighted that spot Bitcoin ETFs have amassed $136 billion in assets under management within 16 months, and noted that firms tied to political figures plan to raise up to $25 billion. TD Cowen reiterated a Buy rating on Strategy with a $590 price target, citing the first-ever at-the-market equity program for its STRF preferred stock, which may create greater accretion for common shareholders. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
FTRE Q1 CY2025 Earnings Call: Revenue Miss, Adjusted Profit Beat, and CEO Transition
Clinical research company Fortrea Holdings (NASDAQ:FTRE) fell short of the market's revenue expectations in Q1 CY2025, with sales falling 1.6% year on year to $651.3 million. Its non-GAAP profit of $0.02 per share was significantly above analysts' consensus estimates. Is now the time to buy FTRE? Find out in our full research report (it's free). Revenue: $651.3 million (1.6% year-on-year decline) Adjusted EPS: $0.02 vs analyst estimates of -$0.07 (significant beat) Adjusted Operating Income: $16.43 million vs analyst estimates of $12.79 million (2.5% margin, 28.5% beat) EBITDA guidance for the full year is $185 million at the midpoint, above analyst estimates of $172.7 million Operating Margin: -79.9%, down from -5.6% in the same quarter last year Market Capitalization: $419.2 million Fortrea's first quarter results were shaped by ongoing transformation efforts and the lingering effects of late-stage clinical service bookings prior to the company's spin-off. CEO Tom Pike attributed the modest revenue decline to a project mix weighted toward longer-duration oncology studies and delays in biotech project startups. Management also pointed to improved operational execution following the divestiture of the Enabling Services business and the exit from transition service agreements. CFO Jill McConnell highlighted that direct personnel costs were reduced significantly through an 8% reduction in permanent headcount, helping offset some revenue softness. However, general and administrative expenses increased due to investments needed to support Fortrea as a standalone public company. Looking ahead, Fortrea's leadership is focused on returning to revenue growth and expanding margins amid a challenging funding environment for biotech customers. Management reaffirmed annual guidance and expects that operating cash flow will improve as invoicing disruptions from the ERP system transition resolve. Interim CEO Peter Neupert, succeeding Tom Pike as part of a planned leadership transition, emphasized the company's commitment to cost optimization and operational efficiency. Jill McConnell noted that ongoing margin improvement will depend on capturing targeted cost reductions and accelerating project burn rates, particularly in biotech and oncology. Management cautioned that macroeconomic and policy uncertainties, as well as delays in customer decision-making, could impact the pace of new business wins. Management attributed the softer revenue to project mix and slower biotech decision-making, while emphasizing progress on cost controls and operational independence post-spin. Oncology Project Mix Impact: The company's revenue burn rate was affected by a portfolio heavily weighted toward oncology trials, which typically progress more slowly due to study complexity, longer durations, and recruitment challenges. Biotech Startup Delays: Decision-making delays among biotech clients, driven by funding uncertainties and a more cautious regulatory environment, contributed to slower project initiations. Management noted these delays have not resulted in cancellations but have extended proposal timeframes. Operational Independence Achieved: Following the exit from transition service agreements tied to its former parent, Fortrea completed significant IT and personnel restructuring. The company reduced permanent headcount by 8% year over year and consolidated its systems and office footprint, supporting early cost savings. Cost Reduction Initiatives: Management detailed $150 million in targeted gross cost reductions for 2025, focusing on both operations and SG&A (selling, general, and administrative expenses). Early progress includes reduced IT spend, a streamlined application portfolio, and facility optimizations. AI and Technology Investments: Fortrea is deploying artificial intelligence tools, including Microsoft Copilot, to enhance productivity in areas such as protocol reviews and commercial workflows. These initiatives are expected to improve efficiency and reduce costs, though management acknowledged that human oversight remains essential due to regulatory requirements. Fortrea's outlook hinges on cost discipline, pipeline execution, and customer funding dynamics, particularly in biotech and oncology segments. Margin Expansion Focus: Management expects that margin gains will be driven by the realization of targeted cost reductions, including further SG&A optimization and increased project burn rates. The timing of savings is weighted toward the second half of the year as restructuring and automation initiatives reach full impact. Biotech Market Uncertainty: The company's ability to restart revenue growth depends on timely customer decision-making and improved funding access for biotech clients. Management cited a growing pipeline, but delays in biotech project starts remain a key risk to near-term growth. Competitive Pricing and Project Mix: Fortrea aims to maintain pricing discipline in a competitive environment, especially as larger contract research organizations (CROs) increase their focus on biotech. The current portfolio's mix of longer-duration and late-stage projects, particularly in oncology, is expected to moderate the pace of backlog conversion and revenue recognition. Looking forward, key items to watch include (1) the pace of new project starts, particularly in biotech and oncology; (2) the company's ability to realize its targeted cost reductions and improve SG&A efficiency; and (3) stabilization of cash flow and reduction of days sales outstanding following the ERP transition. Execution on commercial pipeline conversion and further technology-driven productivity gains will also be key markers of progress. Fortrea currently trades at a forward P/E ratio of 9×. At this valuation, is it a buy or sell post earnings? The answer lies in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
